Prof. Ruth Gabizon Ph.D.

Ruth GabizonAppointment: Professor of Neurobiology, Laboratory of Experimental Neurology, Department of Neurology

Area of expertise: Prion Diseases, biochemistry.

Tel: 02-6777598; Email:


Selected Research Publications

Engelstein R, Ovadia H, Gabizon R (2007) Copaxone interferes with the PrP Sc-GAG interaction. Eur J Neurol 14(8):877-884

Friedman-Levi Y, Ovadia H, Hoftberger R, Einstein O, Abramsky O, Budka H, Gabizon R (2007) Fatal neurological disease in scrapie-infected mice induced for experimental autoimmune encephalomyelitis. J Virol 81(18):9942-9949

Canello T, Engelstein R, Moshel O, Xanthopoulos K, Juanes ME, Langeveld J, Sklaviadis T, Gasset M, Gabizon R (2008)

Methionine sulfoxides on PrPSc: a prion-specific covalent signature. Biochemistry (Mosc) 47(34):8866-8873

Haviv Y, Avrahami D, Ovadia H, Ben-Hur T, Gabizon R, Sharon R (2008) Induced neuroprotection independently from PrPSc accumulation in a mouse model for prion disease treated with simvastatin. Arch Neurol 65(6):762-775

Mayer-Sonnenfeld T, Avrahami D, Friedman-Levi Y, Gabizon R (2008) Chemically induced accumulation of GAGs delays PrP(Sc) clearance but prolongs prion disease incubation time. Cell Mol Neurobiol 28(7):1005-1015

Avrahami D, Dayan-Amouyal Y, Tal S, Mincberg M, Davis C, Abramsky O, Gabizon R (2008) Virus-induced alterations of membrane lipids affect the incorporation of PrP Sc into cells. J Neurosci Res 86(12):2753-2762

Colombo G, Meli M, Morra G, Gabizon R, Gasset M (2009) Methionine sulfoxides on prion protein Helix-3 switch on the alpha-fold destabilization required for conversion. PloS one 4(1):e4296

Oien DB, Canello T, Gabizon R, Gasset M, Lundquist BL, Burns JM, Moskovitz J (2009) Detection of oxidized methionine in selected proteins, cellular extracts and blood serums by novel anti-methionine sulfoxide antibodies. Arch Biochem Biophys 485(1):35-40

Canello T, Frid K, Gabizon R, Lisa S, Friedler A, Moskovitz J, Gasset M (2010) Oxidation of Helix-3 methionines precedes the formation of PK resistant PrP. PLoS Pathog 6(7):e1000977

Lisa S, Meli M, Cabello G, Gabizon R, Colombo G, Gasset M (2010) The structural intolerance of the PrP alpha-fold for polar substitution of the helix-3 methionines. Cell Mol Life Sci 67(16):2825-2838

Meiner Z, Kahana E, Baitcher F, Korczyn AD, Chapman J, Cohen OS, Milo R, Aharon-Perez J, Abramsky O, Gabizon R, Rosenmann H (2010) Tau and 14-3-3 of genetic and sporadic Creutzfeldt-Jakob disease patients in Israel. J Neurol 258(2):255-262

Avrahami D, Gabizon R (2010) Age-related alterations affect the susceptibility of mice to prion infection. Neurobiol Aging 32(11):2006-2015

Canello T, Friedman-Levi Y, Mizrahi M, Binyamin O, Cohen E, Frid K, Gabizon R (2011) Copper is toxic to PrP-ablated mice and exacerbates disease in a mouse model of E200K genetic prion disease. Neurobiol Dis 45(3):1010-1017

Friedman-Levi Y, Meiner Z, Canello T, Frid K, Kovacs GG, Budka H, Avrahami D, Gabizon R (2011) Fatal prion disease in a mouse model of genetic E200K Creutzfeldt-Jakob disease. PLoS Pathog 7(11):e1002350

Friedman-Levi Y, Hoftberger R, Budka H, Mayer-Sonnenfeld T, Abramsky O, Ovadia H, Gabizon R (2012) Targeting of prion-infected lymphoid cells to the central nervous system accelerates prion infection. J Neuroinflammation 9:58

Gabizon R, Brandt T, Sukenik S, Lahav N, Lebendiker M, Shalev DE, Veprintsev D, Friedler A (2012) Specific recognition of p53 tetramers by peptides derived from p53 interacting proteins. PloS one 7(5):e38060

Cohen E, Avrahami D, Frid K, Canello T, Levy Lahad E, Zeligson S, Perlberg S, Chapman J, Cohen OS, Kahana E, Lavon I, Gabizon R (2013) Snord 3A: a molecular marker and modulator of prion disease progression. PloS one 8(1):e54433

Friedman-Levi Y, Mizrahi M, Frid K, Binyamin O, Gabizon R (2013) PrP(ST), a soluble, protease resistant and truncated PrP form features in the pathogenesis of a genetic prion disease. PloS one 8(7):e69583

Friedman-Levi Y , Binyamin O, Frid K, Ovadia H, Gabizon R. Hum Mol Genet (2014) Genetic prion disease:
no role for the immune system in disease pathogenesis? Mar 25. [Epub ahead of print]

Mizrahi M, Friedman-Levi Y, Larush L, Frid K, Binyamin O, Dori D , Fainstein N, Ovadia H, Ben-Hur T, Magdassi S, Gabizon R (2014) Pomegranate Seed oil nanoemulsions for the prevention and treatment of neurodegenerative diseases: The case of genetic CJD. Nanomedicine, March 2014.